While much of the world is understandably focused on the new coronavirus’s emergence in China, three recent developments involve the potential expansion of treatments for an entrenched disease there: cancer.
One biotech is making it easier for patients to keep taking its checkpoint inhibitor, one pharma giant has won approval for a new type of cancer its targeted drug therapy can treat, and another major pharma has won the go-ahead for a combination therapy.
